Treatment of non small cell lung cancer;Léčebné postupy u nemalobuněčného karcinomu plic

Klinicka Onkologie

Volumn 21, Issue 6, 2008, Pages 317-329

  Skřičková, Jana ^a   Coupek P ^a   Babickova L ^a   Tomiskova M ^a   Kaplanova J ^a   Princ, D ^a   Kadlec, B ^a   Spelda S ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Chemotherapy; Non small cell lung cancer; Radiotherapy; Targeted therapy

Indexed keywords

AVASTATIN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE COURSE; HUMAN; INTERMETHOD COMPARISON; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; REVIEW; LUNG TUMOR; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 58149147629     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Zatloukal P, Petruželka L. Karcinom plic. Grada, Praha, 2001: 367
2. Skřičková J, Špelda S, KaplanováJ, a kol. Bronchogenní karcinom (33-53). In: Z. Adam, J. Vorlíč ek, J. Vaníček a kol.: Diagnostické a léč ebné postupy u maligních chorob. Grada Publishing Praha 2002, ISBN 80-7169-792-3, 604
3. Pešek M., et al. Bronchogenní karcinom. Galén, Praha, 2002: 235
4. http://www.svod.cz
5. Ginsberg RJ. Lung Cancer. BC Decker Hamilton, London, 2002: 175
6. Goldstrraw P. Crowley J, Chanski K. et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Griupings in the Forthcoming (Seventh(Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007; 2: 706-714
7. Martins SJ, Pereira JR. Clinical Factors and Prognosis in Non-Small Cell Lung Cancer. Am J Clin Oncol 22; 1999: 453-457
8. Kolek, v, Grygárková, I., Hajdúch M, et al. Neoadjuvantní chemoterapie u hraničně operabilních stádií IIIA nemalobuněčného karcinomu plic kombinací vinorelbin a karboplatina. Následná cílená adjuvantní chemoterapie. Klinická Onkologie 2001; 14: 55-58
9. Le Chevalier T, Arriagada R, Le Pechoux C, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60
10. Molina JR, Dusi AA, Jett JR. Advances in Chemotherapy of Non-small Cell Lung Cancer. CHEST 2006; 130:1211-1219
11. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a metaanalysis of survival outcomes. Lung Cancer 2005;47:69-80
12. Sirohi B, Ashley S, Bortin A. et al. Early Response to Platinum - Based First - Line Chemotherapy in Non-Small Cell Lung Cancer May Predict Surfoval. J thorac Oncol. 2007;2:735-740
13. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR,Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-63
14. Altuang O, Stewart D, Fossella F Vet al. Many Patients over 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy. J Thorac Oncol. 2007;2: 141-146
15. Hennessy BT, Hanrahan EO, Breathach OS. Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer. The Oncologist 2003; 8: 270-277
16. Hanna NH, Shepherd FA., Rosell R. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
17. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25(3):313-318
18. Cerfolio RJ, Bryant AS, Spencer SA et al. Pulmonary resectionafter high-dose and low-dose chest irradiation.Ann Thorac Surg 2005;80(4):1224-1230
19. Bradley JD, Paulus R, Graham MV,et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group- RTOG 9705. J Clin Oncol 2005;23(15):3480-3487
20. Belani CP, Choy H, Bonomi P, et al. Combined chemorediotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell ling cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 2005;23(25):5883-5891
21. Dillman RO, Seagren SL, Herndon J, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer: Five-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.J Clin Oncol (Meeting Abstracts) 1993;12:329
22. Furuse K, Fukuoka M, Kawahara M,et al.Phase III study of concurrent versus senquential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.J Clin Oncol 1999;17:2692-2699
23. International Commission of Radiation Units, Measurement, report no. 62: Prescribing, Recording and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda,MD:ICRU,1999
24. Shennib J, Bogart A, Herndon J. Thoracoscopic wedge resection and radiotherapy for T1N0 non-small cell lung cencer (NSCLC) in high risk patients:preliminary analysisof a CALGB and ACOG Phase II Trial.Int J Radiat Oncol Biol Phys 2000;48(1):232
25. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformala radiotherapy planning. Int J Radiat Oncol Biol Phys 2000;48:1015-1024
26. Grills IS, Fitch DL, Goldstein NS, et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys 2007;69(2):334-341
27. Caldwell CB, Mah K, Ung YC, et al. Obserever variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18 FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 2001;51:923-931
28. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic,quantitative review. Lancet oncology 2001;2:659-666
29. Schalenkamp JM, Miller RC, Brinkmann DH, et al. Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 2007;67(2):410-416
30. Graham MV, Purdy JA,Emani B., et al. Clinical dose-volume histogram for pneumonitis after 3D treatment for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;45(2):323-329
31. Bradly J, Graham MV, Winter K,et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformai radiotherapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2005;61(2):318-328
32. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformai thoracic radiation therapy with induction and cocurent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell ling carcinomas modified phase I/II trial. Cancer 2001;92(5):1213-1223
33. Stejskal j, Cwiertka K, Čoupek P,etal. Karcinomy plic. In: Šlampa P, Petera J. Radiační onkologie, Praha, Galén; 2007. s.171-186
34. Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy: Part II. J Clin Oncol 2002; 20: 3016-3028
35. Niklinski J, Hirsch FR. Molecular approaches to lung cancer evaluation. Lung Cancer 2002; 38: S9-S17
36. Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med 2004; 350: 2129-2139
37. Pham D, Kris MG, McDonough T, et al Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung, ASCO 2005, abstract 7069
38. Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer 2003; 41: S43-S48
39. Shepherd F, Pereira J, Ciuleanu E. et al. Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21, Proc Am Soc Clin Oncol 2004 (post-meeting edition);23;14S (Abstract 7022)
40. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
41. Martins SJ, Pereira JR. Clinical Factors and Prognosis in Non-Small Cell Lung Cancer. Am J Clin Oncol 22; 1999: 453-457
42. Montes JF, Garcia-Valero J, Ferrer J. Evidence of Intervention in Talc-Induced Pleural Adhesions. CHEST 2006; 130:702-709